Viral SARS-CoV-2 Rebound Rates in Linked Commercial Pharmacy-Based Testing and Health Care Claims.

Scott P KellyLisa M McEwenMagnus IsakssonSarah MurphySimon WhiteMatthew E LevyJohn T McCroneGeraint LevanSharad SanthanamMary Lynn BanieckiCandace BramsonHeather RubinoVicky HendrickHolly SoaresJennifer HammondShishi Luo

Published in: Open forum infectious diseases (2024)

Our findings suggest viral RNA rebound is rare (< 5%), with rates that were consistent with those from the EPIC-HR trial (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients). Most occurrences of viral RNA rebound were associated with low viral RNA levels, and viral RNA rebound progression to severe disease was not observed.

Keyphrases

sars cov
respiratory syndrome coronavirus
healthcare
end stage renal disease
newly diagnosed
coronavirus disease
randomized controlled trial
early onset
study protocol